OTC EPINEPHRINE RELABELING TO ADDRESS INAPPROPRIATE USE
This article was originally published in The Tan Sheet
Executive Summary
OTC EPINEPHRINE RELABELING TO ADDRESS INAPPROPRIATE USE was suggested by Nonprescription Drugs Advisory Committee Chair Randy Juhl, PhD, University of Pittsburgh, as one way of dealing with concerns raised during a Nov. 14 joint meeting of NDAC and the Pulmonary-Allergy Drugs Advisory Committee, Speaking in favor of maintaining inhaled epinephrine's OTC availability, Juhl urged the joint committee to "stick with that drug on the OTC market place [and] examine the labeling to see if we can improve it."
You may also be interested in...
CFC Use In OTC Epinephrine Inhalers Topic Of Upcoming NDAC Meeting
FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs advisory committees will discuss the availability of OTC epinephrine metered-dose inhalers (MDIs) and their environmental impact during a joint meeting scheduled for Jan. 24.
CFC Use In OTC Epinephrine Inhalers Topic Of Upcoming NDAC Meeting
FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs advisory committees will discuss the availability of OTC epinephrine metered-dose inhalers (MDIs) and their environmental impact during a joint meeting scheduled for Jan. 24.
CFC Use In OTC Epinephrine Inhalers Topic Of Upcoming NDAC Meeting
FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs advisory committees will discuss the availability of OTC epinephrine metered-dose inhalers (MDIs) and their environmental impact during a joint meeting scheduled for Jan. 24.